{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:06:58Z","timestamp":1756426018265,"version":"3.44.0"},"reference-count":48,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: The Measure of Case-Discussion Complexity (MeDiC) tool was created to gauge case complexity at multidisciplinary team meetings (MDTM) for case selection and prioritization. We aimed to assess applicability and association with MeDiC score and non-compliance with national guideline-recommendations for MDTM referral in a bladder cancer setting.\nMaterial and methods: A modified MeDiC scoring system was applied in 8955 subjects with localized (T1-T4N0M0) or metastasized disease as per the Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. Association between MeDiC score and not being discussed at MDTM was investigated by multivariable logistic regression, and further explored in relation to calendar time period, healthcare region, age at diagnosis and hospital volume.\nResults and interpretation: Median total MeDiC score was lower in individuals not being discussed at an MDTM (7.0 Inter Quartile Range [IQR] 6.0\u20139.0) compared to those who were (8.0 IQR 6.0\u201310.0). Adjusted odds ratio for not being discussed at an MDTM was 2.1 (95% confidence interval [CI] 1.8\u20132.4) for a MeDiC score in the lower quartile, as compared to the highest quartile, with higher estimates when performing stratified analyses in later calendar years and in specific healthcare regions. Our data indicate that the MeDiC score is applicable in bladder cancer patients, and we identified an association between lower MeDiC score and not being discussed at an MDTM.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.42756","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:54:10Z","timestamp":1746492850000},"page":"616-622","source":"Crossref","is-referenced-by-count":0,"title":["Lower MeDiC score is associated with non-referral to multidisciplinary team meeting discussion in bladder cancer patients: a nationwide and population-based study"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-3563","authenticated-orcid":false,"given":"Jessica","family":"Wihl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Oskar Hagberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Firas Aljabery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Truls G\u00e5rdmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Abolfazl Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Staffan Jahnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Tomas Jerlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Viveka Str\u00f6ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Karin S\u00f6derkvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Anders Ull\u00e9n  anders.ullen@sll.se","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Lars Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Christel H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fredrik Liedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"109780","doi-asserted-by":"crossref","unstructured":"Soukup T, Morbi A, Lamb BW, Gandamihardja TAK, Hogben K, Noyes K, et al. A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: mixed methods development and early validation of the MeDiC tool. Cancer Med. 2020;9:5143\u201354.","DOI":"10.1002\/cam4.3026"},{"key":"109781","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.3026","DOI":"10.1002\/cam4.3026"},{"key":"109782","doi-asserted-by":"crossref","unstructured":"Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, et al. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol. 2011;29:78\u201382.","DOI":"10.1016\/j.urolonc.2009.04.008"},{"key":"109783","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.04.008","DOI":"10.1016\/j.urolonc.2009.04.008"},{"key":"109784","doi-asserted-by":"crossref","unstructured":"Gil M, Guerra J, Andrade V, Medeiros M, Guimar\u00e3es T, Bernardino R, et al. The impact of multidisciplinary team conferences in urologic cancer in a tertiary hospital. Int Urol Nephrol. 2021;53:41\u20137.","DOI":"10.1007\/s11255-020-02608-6"},{"key":"109785","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11255-020-02608-6","DOI":"10.1007\/s11255-020-02608-6"},{"key":"109786","doi-asserted-by":"crossref","unstructured":"Gordetsky J, Collingwood R, Lai WS, Del Carmen Rodriquez Pena M, Rais-Bahramiet S. Second opinion expert pathology review in bladder cancer: implications for patient care. Int J Surg Pathol. 2018;26:12\u201317.","DOI":"10.1177\/1066896917730903"},{"key":"109787","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1066896917730903","DOI":"10.1177\/1066896917730903"},{"key":"109788","doi-asserted-by":"crossref","unstructured":"Liedberg F, Kjellstr\u00f6m S, Lind AK, Sherif A, S\u00f6derkvist K, Falkman K, et al. Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scand J Urol. 2022;56:137\u201346.","DOI":"10.1080\/21681805.2022.2041086"},{"key":"109789","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2041086","DOI":"10.1080\/21681805.2022.2041086"},{"key":"109790","doi-asserted-by":"crossref","unstructured":"Lamb BW, Sevdalis N, Benn J, Vincent C, Green JS. Multidisciplinary cancer team meeting structure and treatment decisions: a prospective correlational study. Ann Surg Oncol. 2013;20(3):715\u201322.","DOI":"10.1245\/s10434-012-2691-x"},{"key":"109791","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1245\/s10434-012-2691-x","DOI":"10.1245\/s10434-012-2691-x"},{"key":"109792","doi-asserted-by":"crossref","unstructured":"Ke KM, Blazeby JM, Strong S, Carroll FE, Ness AR, Hollingworth W. Are multidisciplinary teams in secondary care cost-effective? A systematic review of the literature. Cost Eff Resour Alloc. 2013;11(1):7.","DOI":"10.1186\/1478-7547-11-7"},{"key":"109793","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1478-7547-11-7","DOI":"10.1186\/1478-7547-11-7"},{"key":"109794","doi-asserted-by":"crossref","unstructured":"Alexandersson N, Rosell L, Wihl J, Ohlsson B, Steen Carlsson K, Nilbert M. Determinants of variable resource use for multidisciplinary team meetings in cancer care. Acta Oncol. 2018;57(5):675\u201380.","DOI":"10.1080\/0284186X.2017.1400682"},{"key":"109795","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186x.2017.1400682","DOI":"10.1080\/0284186X.2017.1400682"},{"key":"109796","doi-asserted-by":"crossref","unstructured":"Munro AJ. Multidisciplinary team meetings in cancer care: an idea whose time has gone? Clin Oncol (R Coll Radiol) 2015;27(12):728\u201331.","DOI":"10.1016\/j.clon.2015.08.008"},{"key":"109797","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clon.2015.08.008","DOI":"10.1016\/j.clon.2015.08.008"},{"key":"109798","doi-asserted-by":"crossref","unstructured":"Reyes Veliz A, Gray J, Karnon J. Economics of multidisciplinary teams in oncology: a scoping review protocol. JBI Evid Synth. 2020;18(6):1285\u201391.","DOI":"10.11124\/JBISRIR-D-19-00103"},{"key":"109799","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.11124\/jbisrir-d-19-00103","DOI":"10.11124\/JBISRIR-D-19-00103"},{"key":"109800","doi-asserted-by":"crossref","unstructured":"Edney LC, Gray J, Karnon J. A scoping review of the economics of multidisciplinary teams in oncology care. J Cancer Policy. 2020;26:100257.","DOI":"10.1016\/j.jcpo.2020.100257"},{"key":"109801","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jcpo.2020.100257","DOI":"10.1016\/j.jcpo.2020.100257"},{"key":"109802","doi-asserted-by":"crossref","unstructured":"Soukup T, Gandamihardja TAK, McInerney S, Green JSA, Sevdalis N. Do multidisciplinary cancer care teams suffer decision-making fatigue: an observational, longitudinal team improvement study. BMJ Open. 2019;9(5):e027303.","DOI":"10.1136\/bmjopen-2018-027303"},{"key":"109803","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2018-027303","DOI":"10.1136\/bmjopen-2018-027303"},{"key":"109804","doi-asserted-by":"crossref","unstructured":"He C. Multidisciplinary team meetings: barriers to implementation in cancer care. Oncology (Williston Park). 2024;38(9):339\u201344.","DOI":"10.46883\/2024.25921026"},{"key":"109805","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.46883\/2024.25921026","DOI":"10.46883\/2024.25921026"},{"key":"109806","doi-asserted-by":"crossref","unstructured":"Lamprell K, Arnolda G, Delaney GP, Liauw W, Braithwaite J. The challenge of putting principles into practice: resource tension and real-world constraints in multidisciplinary oncology team meetings. Asia Pac J Clin Oncol. 2029;15(4):199\u2013207.","DOI":"10.1111\/ajco.13166"},{"key":"109807","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ajco.13166","DOI":"10.1111\/ajco.13166"},{"key":"109808","doi-asserted-by":"crossref","unstructured":"Walraven JEW, Ripping TM, Oddens JR, van Rhijn BWG, Goossens-Laan CA, Hulshof MCCM, et al. The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer. BJU Int. 2023;131:244\u201352.","DOI":"10.1111\/bju.15856"},{"key":"109809","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.15856","DOI":"10.1111\/bju.15856"},{"key":"109810","doi-asserted-by":"crossref","unstructured":"H\u00e4ggstr\u00f6m C, Hagberg O, G\u00e5rdmark T, Aljabery F, Str\u00f6ck V, Hosseini A, et al. Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. BMJ Open. 2022;12:e064898.","DOI":"10.1136\/bmjopen-2022-064898"},{"key":"109811","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064898","DOI":"10.1136\/bmjopen-2022-064898"},{"key":"109812","doi-asserted-by":"crossref","unstructured":"Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16:e0255239.","DOI":"10.1371\/journal.pone.0255239"},{"key":"109813","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0255239","DOI":"10.1371\/journal.pone.0255239"},{"key":"109814","doi-asserted-by":"crossref","unstructured":"Liedberg F, Hagberg O, Aljabery F, G\u00e5rdmark T, Hosseini A, Jahnson S, et al. Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care: a nationwide population-based study. BJU Int. 2019;124:449\u201356.","DOI":"10.1111\/bju.14767"},{"key":"109815","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.14767","DOI":"10.1111\/bju.14767"},{"key":"109816","doi-asserted-by":"crossref","unstructured":"Wihl J, Falini V, Borg S, Stahl O, Jiborn T, Ohlsson B,et al. Implementation of the measure of case discussion complexity to guide selection of prostate cancer patients for multidisciplinary team meetings. Cancer Med. 2023;12:15149\u201358.","DOI":"10.1002\/cam4.6189"},{"key":"109817","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.6189","DOI":"10.1002\/cam4.6189"},{"key":"109818","doi-asserted-by":"crossref","unstructured":"Scarberry K, Ponsky L, Cherullo E, Larchian W, Bodner D, Cooney M, et al. Evaluating the impact of the genitourinary multidisciplinary tumour board: should every cancer patient be discussed as standard of care? Can Urol Assoc J. 2018;12:E403\u20138.","DOI":"10.5489\/cuaj.5150"},{"key":"109819","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5489\/cuaj.5150","DOI":"10.5489\/cuaj.5150"},{"key":"109820","doi-asserted-by":"crossref","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34:289\u201399.","DOI":"10.1016\/j.annonc.2022.11.012"},{"key":"109821","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2022.11.012","DOI":"10.1016\/j.annonc.2022.11.012"},{"key":"109822","doi-asserted-by":"crossref","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390:875\u201388.","DOI":"10.1056\/NEJMoa2312117"},{"key":"109823","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2312117","DOI":"10.1056\/NEJMoa2312117"},{"key":"109824","doi-asserted-by":"crossref","unstructured":"Okada M, Shindo T, Fujino K, Maeda T, Ito N, Takahashi A, et al. Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy. Support Care Cancer. 2023;31:607.","DOI":"10.1007\/s00520-023-08087-6"},{"key":"109825","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00520-023-08087-6","DOI":"10.1007\/s00520-023-08087-6"},{"key":"109826","doi-asserted-by":"crossref","unstructured":"van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 2010;106:206\u201311.","DOI":"10.1111\/j.1464-410X.2009.09100.x"},{"key":"109827","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1464-410X.2009.09100.x","DOI":"10.1111\/j.1464-410X.2009.09100.x"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42756\/50022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42756\/50022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:05:21Z","timestamp":1756404321000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/42756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.42756","relation":{},"ISSN":["1651-226X"],"issn-type":[{"type":"electronic","value":"1651-226X"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}